Alpha 2 agonists in regional anaesthesia practice: Efficient yet safe?

[17] Investigational use of perineural or neuraxial dexmedetomidine without approval from DCGI may place the investigator, the institute and the review board at risk of medical malpractice litigations if there are drug related adverse events. [...]the safety of perineural and neuraxial dexmedetomidi...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of anaesthesia 2014-11, Vol.58 (6), p.681-683
Main Authors: Pankaj, Kundra, Rajan, P Sakthi
Format: Article
Language:English
Subjects:
Analgesics
Anesthesia
Cardiac arrhythmia
Drug dosages
FDA approval
Medical treatment
Meta-analysis
Methods
Neurotoxicity
Regional anesthesia
Studies
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[17] Investigational use of perineural or neuraxial dexmedetomidine without approval from DCGI may place the investigator, the institute and the review board at risk of medical malpractice litigations if there are drug related adverse events. [...]the safety of perineural and neuraxial dexmedetomidine is clearly proven by further approved studies it is safe to avoid its use in neuraxial and perineural routes. [...]for the safe regional anaesthesia practice in patients receiving alpha 2 agonists as adjuvants to LA agents, one should monitor for bradycardia and hypotension, possible excess sedation and subsequent fall in haemoglobin saturation. [...]regulatory board approved and well powered safety studies for the use of perineural dexmedetomidine are available, it is safe to restrict its use in regional anaesthesia practice as an intravenous adjuvant to LA agents for its beneficial sedative and analgesic properties without respiratory depression.
ISSN:0019-5049
0976-2817
DOI:10.4103/0019-5049.147127